Ariceum Therapeutics, a biotech company developing radiopharmaceutical products for the diagnosis and treatment of certain hard-to-treat cancers, has submitted an application with the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) to...
The FDA recently granted approval for Johnson & Johnson’s (J&J) Akeega, a novel first-in-class combination tablet treatment for adults with breast cancer gene (BRCA)-positive, metastatic castration-resistant prostate cancer (mCRPC).
British-Swedish pharma giant, AstraZeneca, has disclosed key preclinical data for AZD5305, its next-generation PARP1 selective inhibitor at the virtual American Association of Cancer Research (AACR) meeting this week.